interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Givosiran Sodium

Generic competition · all medicines · read 12 November 2026

Is there a generic of Givosiran Sodium, and who makes it?

Givosiran Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Givosiran Sodium1 dosage-form group in the Orange Book
0generic makers listed
  1. Givosiran Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Givlaari. No generic is listed as marketed.

2015202020252030203501brand 2019data datePatent 10131907 listed to expire 24 August 2028Patent 8828956 listed to expire 4 December 2028Patent 8106022 listed to expire 12 December 2029Patent 9631193 listed to expire 15 March 2033Patent 10125364 listed to expire 15 March 2033Patent 9133461 listed to expire 30 November 2033Patent 10119143 listed to expire 3 October 2034Patent 11028392 listed to expire 3 October 2034Exclusivity ODE-273 to 20 November 2026
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 20 November 2026Exclusivity ODE-273 Givlaari
  • 24 August 2028Patent 10131907 drug substance
  • 4 December 2028Patent 8828956 drug substance
  • 12 December 2029Patent 8106022 drug substance
  • 15 March 2033Patent 9631193
  • 15 March 2033Patent 10125364 drug substance
  • 30 November 2033Patent 9133461 drug substance
  • 3 October 2034Patent 10119143 drug substance
  • 3 October 2034Patent 11028392 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.